Topics In Alzheimer S Disease

Dementia is a brain disorder that seriously affects a person's ability to carry out daily activities. The most common form of dementia among older people is Alzheimer's Disease (AD), which involves the parts of the brain that control memory, thought and language. Age is the most important known risk factor for AD. The number of people with the disease doubles every 5 years beyond age 65. AD is a slow disease, starting with mild memory loss and ending with severe brain damage. The course the disease takes and how fast changes occur vary from person to person. On average, AD patients live from 8 to 10 years after they are diagnosed, though the disease can last for as many as 20 years. Current research is aimed at understanding why AD occurs and who is at greatest risk for developing it, improving the accuracy of diagnosis and ability to identify who is at risk, developing, discovering and testing new treatments for behavioural problems in patients with AD. This book gathers state-of-the-art research from leading scientists throughout the world which offers important information on understanding the underlying causes and discovering the most effective treatments for Alzheimer's Disease.

Alzheimer’s disease is undoubtedly the major health challenge of our Century with significant social and economic consequences. This Frontiers eBook offers a contribution of 39 innovative papers on the multidimensional and crucial problem of Alzheimer’s disease management and treatment. Several perspectives, research updates, and trials describing methods on potential diagnosis and treatment are presented including biological mechanisms, biomarkers and risk factors for an early and efficient prognosis, diagnosis and prevention. Additionally, while the rapidly increasing Alzheimer’s disease population demands holistic solutions and clinical studies with new therapeutic target approaches, several of the contributive papers present promising drugs targeting Alzheimer’s disease treatment. We give our deepest acknowledgment to all the authors for their important and innovative contributions, to the reviewers for their valuable recommendations on improving the submitting studies and all the Frontiers Editorial team for continuous support.

Provides a definitive overview of the complex ecosystem facilitating Alzheimer's Disease drug research and development. Demonstrates a drug's journey from in the lab, clinical trial testing, regulatory review, and marketing by pharmaceutical companies. Details the use of artificial intelligence, clinical trial management, and financing models.

Assisting someone with Alzheimer’s disease or another illness that causes dementia is incredibly demanding and stressful for the family. Like many disabling conditions, Alzheimer’s disease leads to difficulty or inability to carry out common activities of daily life, and so family members take over a variety of tasks ranging from managing the person’s finances to helping with intimate activities such as bathing and dressing. Key coverage in Caregiving for Alzheimer’s Disease and Related Disorders includes: Early diagnosis and family dynamics Emotional needs of caregivers Developmentally appropriate long-term care for people with Alzheimer’s Family caregivers as members of the Alzheimer’s treatment Team Legal and ethical issues for caregivers Faith and spirituality The economics of caring for individuals with Alzheimer’s disease Cultural, racial, ethnic, and socioeconomic issues of minority caregivers Advances in Alzheimer’s disease research Caregiving for Alzheimer’s Disease and Related Disorders offers a wealth of insights and ideas for researchers, practitioners, and graduate students across the caregiving fields, including psychology, social work, public health, geriatrics and gerontology, and medicine as well as public and education policy makers.

Dementia is a brain disorder that seriously affects a person's ability to carry out daily activities. The most common form of dementia among older people is Alzheimer's Disease (AD), which involves the parts of the brain that control memory, thought and language. Age is the most important known risk factor for AD. The number of people with the disease doubles every 5 years beyond age 65. AD is a slow disease, starting with mild memory loss and ending with severe brain damage. The course the disease takes and how fast changes occur vary from person to person. On average, AD patients live from 8 to 10 years after they are diagnosed, though the disease can last for as many as 20 years. Current research is aimed at understanding why AD occurs and who is at greatest risk for developing it, improving the accuracy of diagnosis and ability to identify who is at risk, developing, discovering and testing new treatments for behavioural problems in patients with AD. This book gathers state-of-the-art research from leading scientists throughout the world which offers important information on understanding the underlying causes and discovering the most effective treatments for Alzheimer's Disease.

Society today, writes Stephen Post, is "hypercognitive": it places inordinate emphasis on people's powers of rational thinking and memory. Thus, Alzheimer disease and other dementias, which over an extended period incrementally rob patients of exactly those functions, raise many dilemmas. How are we to view—and value—persons deprived of what some consider the most important human capacities? In the second edition of The Moral Challenge of Alzheimer Disease, Post updates his highly praised account of the major ethical issues relating to dementia care. With chapters organized to follow the progression from mild to severe and then terminal stages of dementia, Post discusses topics including the experience of dementia, family caregiving, genetic testing for Alzheimer disease, quality of life, and assisted suicide and euthanasia. New to this edition are sections dealing with end-of-life issues (especially artificial nutrition and hydration), the emerging cognitive-enhancing drugs, distributive justice, spirituality, and hospice, as well as a critique of rationalistic definitions of personhood. The last chapter is a new summary of practical solutions useful to family members and professionals.

This new volume of Advances in Pharmacology explores the Current State of Alzheimer's Disease Research and Therapeutics. Chapters cover such topics as the The role heat shock proteins play in the Alzheimer's Theater, Gamma-Secretase as a Target for Alzheimer's Disease, and Identification of protein kinase C for the treatment of dementias. With a variety of chapters and the best authors in the field, the volume is an essential resource for pharmacologists, immunologists and biochemists alike. Explores the current state of Alzheimer's disease research and therapeutics Chapters cover a variety of topics such as the role heat shock proteins play in the Alzheimer's theater, gamma-secretase as a target for Alzheimer's disease, and identification of protein kinase C for the treatment of dementias With the best authors in the field, the volume is an essential resource for pharmacologists, immunologists and biochemists alike